The United States Patent and Trademark Office (USPTO) has published a patent application, identified as US20260083741A1, concerning a specific dosing regimen for the drug sotorasib. The application, filed on December 16, 2022, by inventors Brett E. Houk and Panli Cardona, outlines methods for administering sotorasib to patients diagnosed with cancer that includes a KRAS G12C mutation. A key aspect of the disclosure is its applicability to patients who are also undergoing treatment with a breast cancer resistance protein (BCRP) substrate, such as rosuvastatin.

This filing represents a new patent application related to pharmaceutical treatments. While patent applications do not impose direct compliance obligations on regulated entities, they are crucial for understanding future intellectual property landscapes and potential market exclusivity for specific drug formulations or administration methods. Companies involved in the development, manufacturing, or marketing of sotorasib or related therapies should monitor the progress of this patent application as it could impact future commercialization strategies and competitive dynamics within the oncology sector.